Silence Therapeutics (NASDAQ:SLN) Hits New 12-Month High – Time to Buy?

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report)’s share price hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $19.87 and last traded at $19.8250, with a volume of 6,521 shares changing hands. The stock had previously closed at $19.82.

Wall Street Analyst Weigh In

SLN has been the topic of several research analyst reports. William Blair lowered Silence Therapeutics from an “outperform” rating to a “hold” rating in a research report on Monday, October 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, October 15th. Jefferies Financial Group cut Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target on the stock. in a report on Monday, October 19th. Chardan Capital downgraded shares of Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 21st. Finally, Morgan Stanley increased their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Silence Therapeutics presently has a consensus rating of “Hold” and an average price target of $24.00.

Read Our Latest Stock Report on SLN

Silence Therapeutics Stock Performance

The stock has a fifty day moving average price of $15.02 and a 200-day moving average price of $9.98. The firm has a market cap of $1.23 billion, a PE ratio of -18.53 and a beta of 1.34.

Silence Therapeutics (NASDAQ:SLN – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.13). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 102.72%. As a group, equities analysts predict that Silence Therapeutics PLC Sponsored ADR will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SLN. Soleus Capital Management L.P. grew its stake in Silence Therapeutics by 278.7% during the 3rd quarter. Soleus Capital Management L.P. now owns 2,385,700 shares of the company’s stock valued at $26,076,000 after purchasing an additional 1,755,700 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of Silence Therapeutics in the 3rd quarter worth about $5,314,000. 5AM Venture Management LLC acquired a new position in Silence Therapeutics in the second quarter valued at approximately $5,228,676. Goldman Sachs Group Inc. boosted its position in Silence Therapeutics by 196.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 462,831 shares of the company’s stock valued at $5,059,000 after purchasing an additional 306,902 shares during the period. Finally, Aberdeen Group plc acquired a new position in shares of Silence Therapeutics during the third quarter valued at $2,207,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

(Get Free Report)

Silence Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce production of specific disease-related proteins. Its proprietary mRNAi GOLD platform is designed to create small interfering RNA (siRNA) medicines, including treatments that target genes expressed in the liver. The company’s research and development programs have included zerlasiran, which targets lipoprotein(a), a risk factor for cardiovascular disease, and divesiran, investigated for blood disorders.

Further Reading

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.